He Zhiheng H, Li Yan, Trivedi Nitin, Gill Sabrina, Hennessey James V
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Cambridge Health Alliance, Cambridge, MA, USA.
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Drugs Context. 2020 Jan 15;9. doi: 10.7573/dic.2019-8-4. eCollection 2020.
Excessive exogenous thyroid hormone ingestion may lead to severe thyrotoxicosis and cause potential harm. We have reviewed the literature and suggested that thyroid hormone supplementation should not be used to alleviate nonspecific complaints in patients with normal endogenous thyroid function. Failure to do so may cause serious harm, as demonstrated in one of the cases described here. In addition, treatment based on symptom relief only without biochemical measure may lead to overmedication - as reported from academic hospitals both in Canada and the United States. Given the risk of severe thyrotoxicosis from potential compounding errors, pharmacies providing a compounding service should be subject to more rigorous monitoring by the food and drug administration. Clinicians should also use local biochemical markers when titrating thyroid hormone supplements even though the normal thyroid function reference range has its limitation, failure to do so may result in iatrogenic thyrotoxicosis.
过量摄入外源性甲状腺激素可能导致严重的甲状腺毒症并造成潜在危害。我们查阅了文献并建议,对于内源性甲状腺功能正常的患者,不应使用甲状腺激素补充剂来缓解非特异性症状。如此做可能会造成严重危害,如下文所述的一个病例所示。此外,仅基于症状缓解而无生化指标监测的治疗可能导致用药过量,加拿大和美国的学术医院均有相关报道。鉴于潜在的配药错误可能导致严重甲状腺毒症的风险,提供配药服务的药房应接受食品药品管理部门更严格的监管。临床医生在调整甲状腺激素补充剂剂量时,也应使用当地的生化指标,尽管正常甲状腺功能参考范围存在局限性,但不这样做可能会导致医源性甲状腺毒症。